What's Happening?
Paris-based One Biosciences, a startup supported by Institut Curie, is establishing its first U.S. location in Albany, New York. The company plans to set up a high-complexity laboratory and computational analytics operation. This expansion is supported by Empire
State Development, which is offering up to $525,000 in performance-based Excelsior Jobs Program tax credits. In return, One Biosciences has committed to creating 42 life science jobs and investing $18 million over the next five years. The company aims to leverage its proprietary single-cell profiling technology to address unmet clinical and scientific needs in characterizing tumor ecosystems. Vincent Miller, MD, the executive chairman of One Biosciences, expressed enthusiasm about collaborating with local researchers and physicians to enhance health outcomes through AI-driven technologies.
Why It's Important?
The establishment of One Biosciences in Albany signifies a significant boost to the local life sciences sector, potentially positioning the region as a hub for cutting-edge medical research and innovation. The company's focus on single-cell profiling technology could lead to advancements in understanding and treating complex diseases, particularly cancer. This move aligns with New York State's strategic efforts to attract high-tech and life sciences companies, fostering economic growth and job creation. The investment and job commitments are expected to stimulate the local economy and enhance the state's reputation as a leader in life sciences research and development.
What's Next?
As One Biosciences sets up its operations in Albany, the company will likely begin recruiting for the 42 promised positions, focusing on attracting skilled professionals in the life sciences field. The development of the lab and analytics operation will be closely watched by industry stakeholders, as it could lead to collaborations with pharmaceutical, biotech, and academic institutions. The success of this expansion could encourage other international biotech firms to consider New York as a viable location for U.S. operations, further strengthening the state's life sciences ecosystem.
